Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Expansion Is Reshaping Competitive Dynamics Across The Industry
Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Expansion From $9.49 Billion In 2026 To $15.22 Billion In 2030
The deoxyribonucleic acid (dna) sequencing in drug discovery market has seen rapid expansion in recent years. It is anticipated to grow from $8.46 billion in 2025 to $9.49 billion in 2026, at a compound annual growth rate (CAGR) of 12.3%. The growth witnessed historically can be linked to increased investment in genomic research, the expansion of pharmaceutical R&D pipelines, the availability of high-throughput sequencing platforms, a growing emphasis on personalized medicine, and advancements in sequencing accuracy and speed.
The deoxyribonucleic acid (dna) sequencing in drug discovery market is anticipated to experience substantial growth in the upcoming years. It is projected to reach $15.22 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 12.5%. This expansion during the forecast period is largely driven by factors such as the increasing integration of AI-powered genomic analysis, the rising requirement for targeted therapeutic solutions, the broadening applications of pharmacogenomics, the expanding utilization of sequencing in early drug screening phases, and enhanced collaborations between pharmaceutical and biotechnology enterprises. Noteworthy trends for the forecast period include a greater deployment of next-generation sequencing for target identification, the increasing embrace of single-cell sequencing methodologies, deeper incorporation of bioinformatics into drug discovery, the expansion of precision medicine research programs, and a heightened emphasis on drug development guided by biomarkers.
Download A Free Sample Report For Comprehensive Market Insights:
#Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Demand Drivers Creating New Revenue Opportunities
The increasing need for personalized medicine is anticipated to fuel the expansion of deoxyribonucleic acid (DNA) sequencing within the drug discovery market in the future. This medical strategy involves customizing disease prevention, diagnosis, and therapy based on a person’s unique genetic profile, lifestyle choices, and environmental influences. The growing demand for personalized medicine largely stems from breakthroughs in genomics and molecular diagnostics, which facilitate the precise detection of genetic and molecular distinctions between individuals, enabling treatments to be customized for enhanced efficacy and fewer adverse reactions. Deoxyribonucleic acid (DNA) sequencing aids personalized medicine through the identification of genetic variations specific to patients, which in turn supports the creation of targeted treatments, better drug choices, and enhanced treatment effectiveness with fewer undesirable outcomes. As an illustration, in February 2024, the US-based non-profit organization, Personalized Medicine Coalition, reported that in 2023, the Food and Drug Administration (FDA) authorized 16 novel personalized therapies for individuals with rare disease, an increase from six in 2022. Among the new personalized treatments approved in 2023 were seven cancer drugs and three for various other diseases and conditions. Consequently, the increasing need for personalized medicine is propelling the growth of deoxyribonucleic acid (DNA) sequencing within the drug discovery market.
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Segment Landscape: Which Areas Lead Market Development?
The deoxyribonucleic acid (dna) sequencing in drug discovery market covered in this report is segmented –
1) By Product Type: Instruments; Consumables
2) By Workflow: Sample Preparation; Sequencing
3) By Technology Type: Sanger Sequencing; Next-Generation Sequencing (NGS)
4) By Application: Drug Discovery; Pharmacogenomics
5) By End-User: Pharmaceutical Companies; Biotechnology Firms
Subsegments:
1) By Instruments: Sequencing Systems; Sample Preparation Systems; Detection And Imaging Systems; Automation And Robotics Systems; Data Analysis Hardware
2) By Consumables: Sequencing Reagents; Library Preparation Kits; Sample Collection Kits; Flow Cells; Quality Control Reagents
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Trends Driving Strategic Industry Expansion
Leading companies active in the deoxyribonucleic acid (DNA) sequencing in the drug discovery market are concentrating on developing advanced solutions, such as high-resolution DNA methylation sequencing assays, with the goal of accelerating biomarker discovery and precision drug development. These high-resolution DNA methylation sequencing assays are sophisticated genomic techniques that accurately profile DNA methylation at a single-base or near single-base resolution across the genome. This capability allows for an in-depth evaluation of epigenetic changes that control gene activity, thereby aiding a precise understanding of disease biology and the identification of potential drug targets. For instance, in April 2025, EpiCypher Inc., a US-based epigenetics company, launched CUTANA mCUT&RUN and Multiomic CUT&RUN. These two innovative DNA methylation sequencing assays are designed to provide high-resolution methylation profiling with significantly lower sequencing costs and reduced sample input requirements. Such assays enable researchers to simultaneously analyze DNA methylation and chromatin features, offering deeper multiomic insights into gene regulation mechanisms. These advancements in assay technology support faster and more cost-effective target identification and validation, thus expediting drug discovery and development processes.
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Industry Leaders And Market Competition
Major companies operating in the deoxyribonucleic acid (dna) sequencing in drug discovery market are Thermo Fisher Scientific Inc., Eurofins Genomics GmbH, Agilent Technologies Inc., Illumina Inc., Revvity Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., 10x Genomics Inc., BGI Genomics, Azenta Life Sciences, Oxford Nanopore Technologies plc, Pacific Biosciences of California Inc., Element Biosciences Inc., Macrogen Inc., Ultima Genomics Inc., SOPHiA GENETICS SA, ProPhase Labs Inc., Singular Genomics Systems Inc., Psomagen Inc., and QitanTech Co Ltd.
Access The Complete Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Report:
Deoxyribonucleic Acid (DNA) Sequencing In Drug Discovery Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the deoxyribonucleic acid (DNA) sequencing in drug discovery market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the deoxyribonucleic acid (dna) sequencing in drug discovery market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
